COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 15, 2022
September 15, 2022

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Tirzepatide Reduces Time to HbA1c Targets by Up to 3 Months vs Semaglutide, Insulin Degludec
September 15, 2022

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

The Brunt of the Long COVID Patient Burden May Fall on Primary Care, says Rehabilitation Medicine Expert
September 15, 2022

NYU Langone Rusk Rehabilitation medical director Steven Flanagan, MD, discusses the "second crisis" of the pandemic and the impact on primary care.

COPD: Pulmonary Rehab is Effective Regardless of Inhaled Triple Therapy Use
September 15, 2022

In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.

Arthritis in Older Adults: Patient Thoughts on Symptoms, Management, & Clinician Counseling
September 14, 2022

New findings from a national survey shed light on patient attitudes and experiences with arthritis and joint pain.

Nocturnal Hypertension: 8 Essential Questions
September 14, 2022

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Take-home Messages for Acute Pain Management
September 14, 2022

Benjamin W. Friedman, MD, MS; Francesca Beaudoin, MD, MS, PhD; Paul Arnstein, RN, PhD, FAAN; and Jeff Gudin, MD, provide take-home messages to providers treating patients with acute pain.

Impressions From Case 2
September 14, 2022

Drs Francesca Beaudoin, Paul Arnstein, and Jeff Gudin discuss clinical impressions about the case of a 27-year-old man with acute pain.

Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
September 14, 2022

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

Long COVID Presents Many More Questions than Answers, says AAPM&R President-elect Flanagan
September 14, 2022

Long COVID symptoms are reported by persons who have had only mild disease, who have been vaccinated and boosted, and even those who had asymptomatic infection.